Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia
During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality.
Authors
- Behzad Hajarizadeh (ORCID: https://orcid.org/0000-0003-2212-2028)
- Jacob George (ORCID: https://orcid.org/0000-0002-8421-5476)
- Sallie‐Anne Pearson (ORCID: https://orcid.org/0000-0001-7137-6855)
- Shane Tillakeratne (ORCID: https://orcid.org/0000-0002-5988-3579)
- Maryam Alavi (ORCID: https://orcid.org/0000-0003-3512-4938)
- Jason Grebely (ORCID: https://orcid.org/0000-0002-1833-2017)
- Gregory J. Dore (ORCID: https://orcid.org/0000-0002-4741-2622)
- Gail Matthews (ORCID: https://orcid.org/0000-0002-1048-6396)
- Heather Valerio (ORCID: https://orcid.org/0000-0002-8608-2558)
- Marianne Martinello
Institutions
- The University of Sydney (AU)
- Westmead Hospital (AU)
- UNSW Sydney (AU)
- Westmead Institute (AU)
- Westmead Institute for Medical Research (AU)
- Data61 (AU)
Publication Details
- Journal
- International Journal of Drug Policy
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1016/j.drugpo.2025.104790
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Health and Aged Care, Australian Government
- NSW Ministry of Health
- National Health and Medical Research Council